{"id":1693,"date":"2023-12-04T10:40:47","date_gmt":"2023-12-04T02:40:47","guid":{"rendered":"https:\/\/www.1ai.net\/?p=1693"},"modified":"2023-12-04T10:40:47","modified_gmt":"2023-12-04T02:40:47","slug":"%e9%98%bf%e6%96%af%e5%88%a9%e5%ba%b7%e4%b8%8e-ai-%e7%94%9f%e7%89%a9%e5%88%b6%e8%8d%af%e5%85%ac%e5%8f%b8-absci-%e7%ad%be%e7%bd%b2%e4%bb%b7%e5%80%bc-2-47-%e4%ba%bf%e7%be%8e%e5%85%83%e7%9a%84%e5%8d%8f","status":"publish","type":"post","link":"https:\/\/www.1ai.net\/en\/1693.html","title":{"rendered":"AstraZeneca and AI biopharmaceutical company Absci sign $247 million agreement to collaborate on cancer drug development"},"content":{"rendered":"<p>British and Swedish pharmaceutical company AstraZeneca and the U.S.<a href=\"https:\/\/www.1ai.net\/en\/tag\/%e4%ba%ba%e5%b7%a5%e6%99%ba%e8%83%bd\" title=\"[View articles tagged with [artificial intelligence]]\" target=\"_blank\" >AI<\/a>\uff08<a href=\"https:\/\/www.1ai.net\/en\/tag\/ai\" title=\"[View articles tagged with [AI]]\" target=\"_blank\" >AI<\/a>) Biologics Company <a href=\"https:\/\/www.1ai.net\/en\/tag\/absci\" title=\"_Other Organiser\" target=\"_blank\" >Absci<\/a> Signed a $247 million agreement to design a<span class=\"spamTxt\">Anti-cancer<\/span>The company has developed antibodies to fight the disease, Absci said in a statement on Sunday.<\/p>\n<p class=\"article-content__img\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-1694\" title=\"201811151621144622_55\" src=\"https:\/\/www.1ai.net\/wp-content\/uploads\/2023\/12\/201811151621144622_55.jpg\" alt=\"201811151621144622_55\" width=\"600\" height=\"397\" \/><\/p>\n<p>Absci\u2019s collaboration with AstraZeneca aims to develop a zero-shot AI model designed to create new and improved antibody therapeutics. The company did not say which types of cancer they plan to target.<\/p>\n<p>Absci applies generative AI to design products based on target affinity, safety, manufacturability, and other characteristics.<span class=\"spamTxt\">optimal<\/span>Drug candidates.<\/p>\n<p>Absci CEO Sean McClain said: \u201cWe are proud to be working closely with AstraZeneca to use our AI to<span class=\"spamTxt\">Tumor<\/span>Patients bring new treatment options.\u201d<\/p>\n<p>According to the Financial Times<span class=\"spamTxt\">first<\/span>reported the deal, which includes a one-time fee for Absci, research and development funding, payments for achieving milestones, and royalties on any product sales.<\/p>","protected":false},"excerpt":{"rendered":"<p>British-Swedish pharmaceutical company AstraZeneca has signed a deal worth up to $247 million with U.S.-based artificial intelligence (AI) biologics company Absci to design an antibody for use against cancer, Absci said in a statement on Sunday. Absci's collaboration with AstraZeneca aims to develop a zero-generation AI model that is designed to create new and improved antibody therapeutics. The company did not specify which types of cancer they plan to target. Absci applies generative AI to design the best drug candidates based on target affinity, safety, manufacturability and other characteristics. Absci CEO Sean McClain said, \"We are proud to work closely with AstraZeneca to utilize my<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[146],"tags":[543,411,204],"collection":[],"class_list":["post-1693","post","type-post","status-publish","format-standard","hentry","category-news","tag-absci","tag-ai","tag-204"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/posts\/1693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/comments?post=1693"}],"version-history":[{"count":0,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/posts\/1693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/media?parent=1693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/categories?post=1693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/tags?post=1693"},{"taxonomy":"collection","embeddable":true,"href":"https:\/\/www.1ai.net\/en\/wp-json\/wp\/v2\/collection?post=1693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}